SCHEMBL497604

SCHEMBL497604

[CH2]CCCC(=O)N(CC)CC

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.73
ALDH1A1 P00352 4/20 0.41
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
NPC1 O15118 2/20 0.39
TSHR P16473 2/20 0.39
HPGD P15428 2/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GBA1 P04062 2/20 0.36
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
TSPO P30536 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498180 0.93 LMNA (0.70) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL989052 0.91 LMNA (0.67) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL5542370 0.91 LMNA (0.67) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL7555392 0.91 LMNA (0.67) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL7554998 0.91 LMNA (0.67) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL7558507 0.91 LMNA (0.67) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL7556079 0.91 LMNA (0.67) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL5209308 0.87 LMNA (0.56) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL5208505 0.86 LMNA (0.54) LMNAALDH1A1MMP1MMP2MMP3
SCHEMBL231479 0.85 LMNA (0.64) LMNAALDH1A1MMP1MMP2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261155-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2022-03-01 US disclosed
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2021-04-15 US disclosed
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2020-06-30 US disclosed
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2019-11-05 US disclosed
EP-3305763-B1 DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS KYORIN SEIYAKU KK (JP) 2019-07-24 EP disclosed
US-20190161445-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2019-05-30 US disclosed
US-10252992-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2019-04-09 US disclosed
US-20180290974-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2018-10-11 US disclosed
US-10029983-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2018-07-24 US disclosed
EP-3305763-A1 DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS Kyorin Pharmaceutical Co., Ltd. (JP) 2018-04-11 EP disclosed
US-5254595-A Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them ELF SANOFI (FR) 1993-10-19 US disclosed
US-5236921-A Administrering for treatment of neutrogenic inflammation of the respiratory trart SANOFI (FR) 1993-08-17 US disclosed
US-4988718-A Fungicides for plants BAYER AKTIENGESELLSCHAFT (DE) 1991-01-29 US disclosed
US-4968687-A AGRICULTURAL FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 1990-11-06 US disclosed
US-4950648-A SUBSTITUTED PYRIDO(2,3-D) OR PYRIMIDO(4,5-D) PYRIMIDINE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1990-08-21 US disclosed
EP-0359078-A1 Substituted heterocyclyl-oximino-pyrazolin-5-ones, method for their preparation and their use as herbicides BAYER AG (DE) 1990-03-21 EP disclosed
EP-0200915-B1 AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM Roche Diagnostics GmbH (DE) 1989-09-27 EP disclosed
US-4863949-A CARDIOVASCULAR DISORDER TREATMENT BOEHRINGER MANNHEIM GMBH (DE) 1989-09-05 US disclosed
EP-0280951-A1 Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates Roche Diagnostics GmbH (DE) 1988-09-07 EP disclosed
EP-0200915-A1 Aminopropanol derivatives, process for their preparation, their use and medicines containing them Roche Diagnostics GmbH (DE) 1986-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-20180290974-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-10029983-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-20190161445-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-10252992-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885
US-11261155-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 LMNA 4414/4885ALDH1A1 2202/4885MMP1 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.